Focus in 4 Days – Drug-Free ADHD Relief

Ideal candidates are aged 15 – 65 with a documented ADHD diagnosis who have not achieved adequate symptom control—or have experienced intolerable side-effects—on stimulant or non-stimulant medication. We exclude clients with metal implants above the shoulders, active seizure disorders, unstable cardiac conditions, or untreated substance-use disorders. Every prospective patient completes a medical questionnaire, qEEG screening, and psychiatric evaluation before scheduling.

Each morning and afternoon you receive a 10-minute train of intermittent theta-burst stimulation (iTBS) every 50 minutes. While stimulation is delivered, you wear a VR headset running proprietary focus-training tasks that engage the dorsolateral pre-frontal cortex. Day 1 and Day 4 include baseline and post-treatment cognitive testing, qEEG mapping, and a doctor visit to track objective gains.

Theta-burst TMS is FDA-cleared for major depressive disorder and OCD. Multiple peer-reviewed studies now show robust improvements in ADHD symptom scores, so we provide it as an evidence-based “off-label” therapy, following the same safety limits used in FDA trials and under the supervision of board-certified psychiatrists.

Research suggests that coupling neuromodulation with concurrent cognitive engagement amplifies neuroplasticity. Our VR tasks demand sustained visual attention and response inhibition—two networks often under-activated in ADHD—so the stimulated circuits are being exercised at the exact moment they are primed for change.

Most people describe a rhythmic tapping on the scalp accompanied by a clicking sound, similar to a distant metronome. Roughly 1 in 4 patients notice mild scalp tenderness or tension headache after the first block; symptoms usually resolve within a few hours and respond to over-the-counter analgesics. No sedation or recovery time is needed—you can drive yourself home each day.

Around 60 % of clients report sharper focus, fewer careless errors, and reduced impulsivity within the first week. Objective gains on Conners CPT-3 and Barkley Executive Function scales generally peak at the 30-day follow-up. Continued improvement through the 3-month mark is common as cortical networks consolidate.

In our clinic registry, symptom relief persists six to twelve months for most adults. If attention drifts noticeably, a single “booster” day (two iTBS blocks) every three to four months is usually sufficient. We reassess each patient at six months and tailor maintenance only when clinically indicated.

Yes. Medication may continue unchanged. To avoid masking baseline measures, we ask that you take your regular morning dose after the first stimulation block each day.

iTBS was originally cleared for depression and shows strong data for generalized anxiety. Many ADHD clients experience parallel reductions in rumination, social anxiety, and low mood, likely because the same pre-frontal circuits underlie both attention and emotional regulation.

We combine iTBS with dual-field VR, use qEEG-guided targeting, and compress 80 stimulus sessions into four consecutive days—maximising neuroplastic drive while minimising life disruption. All procedures occur in a physician-led outpatient suite, and transparent, flat-rate pricing with 0 % financing keeps the process predictable.